|
|
| | Maprotiline hydrochloride Basic information |
| | Maprotiline hydrochloride Chemical Properties |
| Melting point | 230-232°C | | Fp | 9℃ | | storage temp. | 2-8°C | | solubility | H2O: 50 mg/mL | | form | powder | | color | white | | Water Solubility | Soluble to 50mg/ml in water. Soluble in ethanol at 10mM | | Merck | 14,5748 |
| Hazard Codes | Xn,T,F | | Risk Statements | 22-39/23/24/25-23/24/25-11 | | Safety Statements | 7-16-36/37-45 | | RIDADR | 3249 | | WGK Germany | 3 | | RTECS | KJ4555000 | | HazardClass | 6.1(b) | | PackingGroup | III | | HS Code | 2921490002 | | Toxicity | LD50 in mice, rats (mg/kg): ~750, ~900 orally (Hess) |
| | Maprotiline hydrochloride Usage And Synthesis |
| Description | Maprotiline is a tricyclic antidepressant. It binds to the norepinephrine transporter (NET; Kd = 11 nM) and is selective for NET over the serotonin (5-HT) and dopamine transporters (Kds = 5,800 and 1,000 nM, respectively). Maprotiline also binds to the 5-HT receptor subtype 5-HT2A (KI = 51 nM), as well as histamine H1, muscarinic acetylcholine, α1-adrenergic, and dopamine D2 receptors (Kds = 2, 570, 90, and 350 nM, respectively). In vivo, maprotiline inhibits norepinephrine reuptake in rat brain and peripheral tissues. It reduces isolation-induced aggressive behavior and inhibits electrical foot-shock stimulation-induced belligerence in mice when administered at doses ranging from 3 to 10 mg/kg. Maprotiline (20 μM) prevents acid sphingomyelinase activation and subsequent ceramide release induced by infection with replication-deficient vesicular stomatitis virus pseudoviral particles (pp-VSV) presenting the severe acute respiratory coronavirus 2 (SARS-CoV-2) spike protein in Vero cells, an effect that can be overcome with exogenous application of C16 ceramide . Formulations containing maprotiline have been used in the treatment of depression and anxiety. This product is also available as an analytical reference material (Item Nos. 32702 | 33077). | | Chemical Properties | Crystalline Solid | | Originator | Maprotiline hydrochloride ,Mylan | | Uses | estrogen, with progesterone as oral contraceptive | | Uses | Antidepressant | | Uses | Maprotiline Hydrochloride has also been shown to block apoptosis of spiny neurons and inhibit SLC6A2. | | Definition | ChEBI: Maprotiline hydrochloride is a member of anthracenes. | | Manufacturing Process | 9-(3-Hydroxypropyl)anthracene was prepared by reduction of 3-(9-anthryl) propionic acid with LiAlH4. By action of thionylchloride and then methylamine the 9-(3-hydroxypropyl)anthracene was converted to 9-(3-methylaminopropyl) anthracene. By addition of ethylene to 9-(3-methylaminopropyl)anthracene (at 150°C, a pressure of ethylene 50 atm, 24 hours) was obtained 3-(9,10- dihydro-9,10-ethanoanthracene-9-yl)-N-methylpropylamine. Hydrochloride 3- (9,10-dihydro-9,10-ethanoanthracene-9-yl)-N-methylpropylamine may be prepared by action hydrochloric acid. | | Therapeutic Function | Antidepressant | | General Description | Maprotiline hydrochloride, N-methyl-9,10-ethanoanthracene-9(10H)-propanamine hydrochloride (Ludiomil), is sometimesdescribed as a tetracyclic rather than a tricyclic antidepressant.The description is chemically accurate, but the compound,nonetheless, conforms to the overall TCA pharmacophore. Itis a dibenzobicyclooctadiene and can be viewed as a TCAwith an ethylene-bridged central ring. The compound is notstrongly anticholinergic and has stimulant properties. It canhave effects on the cardiovascular system. It is a SNERI. | | Biological Activity | Selective noradrenalin re-uptake inhibitor. |
| | Maprotiline hydrochloride Preparation Products And Raw materials |
|